Search clinical trials for: MVA-CSO Vaccine

Total 10093 results

National Institute of Allergy and Infectious Diseases...

Withdrawn

CS DNA MVA Trial in Mampong, Ghana

Plasmodium Falciparum Malaria

Ghana, United States
National Institute of Allergy and Infectious Diseases...

Completed

Combination Study With MVA BN and Dryvax

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

HIV Infections

Uganda, United States, Kenya, Tanzania
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

United States
University of Oxford
Medical Research Council

Completed

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

TB

Gambia
National Institute of Allergy and Infectious Diseases...

Withdrawn

Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications

HIV Infections
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus

Cytomegalovirus Infection | Healthy, no Evidence of Disease

United States
University of Oxford

Completed

A Study of the Safety and Effectiveness of Two New Malaria Vaccines

Malaria

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Early Immune Responses to Vaccination - A Substudy to HVTN 205

HIV Infections

United States
University of Oxford
University of Cape Town

Completed

A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both

HIV Infections | TB

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Yellow Fever | Yellow Fever Immunisation

United States
National Cancer Institute (NCI)

Recruiting

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Lynch Syndrome

United States, Puerto Rico
GeoVax, Inc.
National Cancer Institute (NCI); City of Hope Medical Center

Active, not recruiting

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

COVID-19 Infection

United States
GeoVax, Inc.
National Cancer Institute (NCI)

Recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Lymphoma | Leukemia | Plasma Cell Myeloma | Hematopoietic and Lymphoid System Neoplasm | COVID-19 Infection

United States
Ivan Litvinov

Terminated

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)

Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...

Completed

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Ebola Disease | Marburg Disease

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

HIV Infections

United States, South Africa
City of Hope Medical Center
National Cancer Institute (NCI); Diavax Biosciences

Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Lymphadenopathy | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated Phase... and other conditions

United States
City of Hope Medical Center

Withdrawn

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Hematopoietic Cell Transplantation Recipient | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated... and other conditions

United States
University of Oxford

Completed

Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS

Malaria

Ireland
Chinese University of Hong Kong

Completed

Modified Vaccinia Ankara (MVA) Vaccine Study

Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections

Hong Kong
Vaccitech (UK) Limited
University of Oxford

Terminated

Improved Novel VaccIne CombinaTion InflUenza Study (INVICTUS)

Influenza

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

Smallpox

United States
Muhimbili University of Health and Allied Sciences
Karolinska Institutet; Imperial College London; Medical Research Council; Ludwig-Maximilians... and other collaborators

Completed

A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique (TaMoVac II)

HIV | Safety | Immunogenicity | Vaccines

Tanzania, Mozambique
GeoVax, Inc.
University of Alabama at Birmingham; AIDS Research Consortium of Atlanta; AIDS...

Completed

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

HIV-1 Infection

United States
Centers for Disease Control and Prevention
Bavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...

Active, not recruiting

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Monkeypox Virus Infection

Congo, The Democratic Republic of the
ANRS, Emerging Infectious Diseases
Imperial College London; University College, London; Fred Hutchinson Cancer Center and other collaborators

Terminated

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection (EHVAT01)

HIV-1-infection

Switzerland, United Kingdom
Masonic Cancer Center, University of Minnesota

Completed

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Lymphoma | Multiple Myeloma

United States
Cancer Research UK

Completed

A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma

Nasopharyngeal Cancer | Epstein Barr Virus Infections

United Kingdom
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

HIV Infections | Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Withdrawn

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

Atopic Dermatitis | Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine

Smallpox
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | COVID-19 Infection

United States
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...

Recruiting

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

Monkeypox

Congo, The Democratic Republic of the
National Institute of Allergy and Infectious Diseases...
GeoVax, Inc.

Completed

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

HIV Infections

United States
Marylyn Addo
Charite University, Berlin, Germany; University of Cologne; Ludwig-Maximilians... and other collaborators

Completed

Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S

MERS (Middle East Respiratory Syndrome)

Germany
London School of Hygiene and Tropical Medicine
Medical Research Council; University of Oxford

Completed

Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men

Malaria

Gambia
University of Oxford
Medical Research Council; Ifakara Health Institute

Completed

Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania

Malaria,Falciparum

Tanzania

Search clinical trials for: MVA-CSO Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations